Solid Biosciences (NASDAQ:SLDB) Director Ilan Ganot Sells 7,205 Shares

Solid Biosciences Inc. (NASDAQ:SLDB) Director Ilan Ganot sold 7,205 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $6.44, for a total transaction of $46,400.20. Following the completion of the transaction, the director owned 25,271 shares in the company, valued at approximately $162,745.24. This represents a 22.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Ilan Ganot also recently made the following trade(s):

• On Wednesday, January 28th, Ilan Ganot sold 191 shares of Solid Biosciences stock. The shares were sold at an average price of $6.59, for a total value of $1,258.69.
• On Monday, January 5th, Ilan Ganot sold 1,053 shares of Solid Biosciences stock. The stock was sold at an average price of $5.43, for a total value of $5,717.79.

Solid Biosciences Stock Up 4.7%

SLDB opened at $6.52 on Friday. Solid Biosciences Inc. has a 52 week low of $2.41 and a 52 week high of $7.37. The business has a fifty day simple moving average of $5.84 and a 200-day simple moving average of $5.72. The firm has a market cap of $507.97 million, a P/E ratio of -2.62 and a beta of 2.67.

Wall Street Analysts Forecast Growth

SLDB has been the topic of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Solid Biosciences in a research report on Thursday, January 22nd. Wall Street Zen lowered shares of Solid Biosciences from a “hold” rating to a “sell” rating in a report on Sunday, October 19th. JPMorgan Chase & Co. cut their price objective on Solid Biosciences from $13.00 to $11.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Chardan Capital reiterated a “buy” rating and issued a $15.00 target price on shares of Solid Biosciences in a report on Tuesday, November 4th. Finally, Needham & Company LLC restated a “buy” rating and set a $16.00 price target on shares of Solid Biosciences in a report on Wednesday, January 14th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $14.70.

Key Stories Impacting Solid Biosciences

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Company will present at the Guggenheim Emerging Outlook: Biotech Summit (CEO Bo Cumbo presenting Feb 12) — this gives Solid (SLDB) direct exposure to institutional investors and can support a rally if management provides encouraging clinical, regulatory, or financing updates. Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
• Neutral Sentiment: Trading context: SLDB is trading above recent moving averages with volume notably above its average — this suggests heightened interest but does not by itself indicate direction until drivers (presentation vs. insider sales) dominate.
• Negative Sentiment: CEO Alexander (Alex) Cumbo sold 48,913 shares at an average $6.44 (≈$315k); his holding fell ~18.1% — a large CEO sale can be read negatively by investors even if for personal reasons. CEO Sale SEC Filing
• Negative Sentiment: CFO Kevin Tan sold 14,783 shares at $6.44 (~$95k); his position fell ~13.6% — another senior officer reduction that may weigh on sentiment. CFO Sale SEC Filing
• Negative Sentiment: COO David T. Howton sold 18,894 shares at $6.44 (~$122k); ownership declined ~16.2%. COO Sale SEC Filing
• Negative Sentiment: CTO Paul Herzich sold 10,905 shares at $6.44 (~$70k); holding fell ~13.6%. CTO Sale SEC Filing
• Negative Sentiment: Other insiders — director Ilan Ganot (7,205 shares), insider Jessie Hanrahan (12,348 shares), and Gabriel Brooks (12,616 shares) — each sold at $6.44, reducing holdings by double-digit percentages; collectively these sales increase supply pressure and raise investor questions about insider confidence. Director/Insider Sales SEC Filings

Institutional Trading of Solid Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. Quantum Private Wealth LLC lifted its holdings in Solid Biosciences by 3.9% during the 3rd quarter. Quantum Private Wealth LLC now owns 94,231 shares of the company’s stock worth $581,000 after buying an additional 3,500 shares during the last quarter. Legal & General Group Plc raised its position in shares of Solid Biosciences by 208.6% during the 2nd quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock worth $29,000 after acquiring an additional 4,063 shares in the last quarter. Ameritas Investment Partners Inc. boosted its holdings in Solid Biosciences by 205.5% in the second quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock valued at $33,000 after purchasing an additional 4,534 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in Solid Biosciences by 142.0% during the third quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company’s stock worth $63,000 after purchasing an additional 5,991 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its holdings in Solid Biosciences by 233.8% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 15,113 shares of the company’s stock worth $74,000 after purchasing an additional 10,585 shares in the last quarter. 81.46% of the stock is currently owned by institutional investors and hedge funds.

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.